Outcomes of patients supported on Impella 5.5 for more than 14 days: A Cardiogenic Shock Working Group registry analysis
- 1 July 2025
- journal article
- research article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (10) , 1583-1594
Abstract
No abstract availableKeywords
Funding Information
- Abbott Laboratories
This publication has 18 references indexed in Scilit:
- 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic ShockJACC, 2025
- Factors associated with acute limb ischemia in cardiogenic shock and downstream clinical outcomes: Insights from the Cardiogenic Shock Working GroupThe Journal of Heart and Lung Transplantation, 2024
- Short-Term Outcomes of Heart Transplant Patients Bridged with Impella 5.5 Ventricular Assist DeviceESC Heart Failure, 2023
- Temporary mechanical circulatory support devices: practical considerations for all stakeholdersNature Reviews Cardiology, 2022
- Criteria for Defining Stages of Cardiogenic Shock SeverityJACC, 2022
- A Case Series Analysis on the Clinical Experience of Impella 5.5® at a Large Tertiary Care CentreESC Heart Failure, 2021
- First in man evaluation of a novel circulatory support device: Early experience with the Impella 5.5 after CE mark approval in GermanyThe Journal of Heart and Lung Transplantation, 2021
- Ischemic Stroke and Intracranial Hemorrhages During Impella Cardiac SupportASAIO Journal, 2020
- Use of a percutaneous temporary circulatory support device as a bridge to decision during acute decompensation of advanced heart failureThe Journal of Heart and Lung Transplantation, 2018
- Incidence of Hemolysis in Patients with Cardiogenic Shock Treated with Impella Percutaneous Left Ventricular Assist DeviceASAIO Journal, 2016